Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Grab Holdings Ltd. (GRAB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Grab Holdings Ltd. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.06B), while Grab Holdings Ltd. trades at $3.73 (market cap $14.97B). The key difference: Grab Holdings Ltd. is far larger — about 3× ACADIA Pharmaceuticals Inc.'s market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Grab Holdings Ltd. nearer its low. Which is the better fit depends on your goals.
| ACAD | GRAB | |
|---|---|---|
Market Cap | $5.06B | $14.97B |
Sector | Health | Technology |
52-Week High | $29.41 | $6.45 |
52-Week Low | $20.06 | $3.27 |
Enterprise Value | $4.18B | $10.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.21, up 2.67% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $0.18 versus $0.07 expected, driven by robust Daybue and Nuplazid sales, leading to a raised 2026 revenue outlook. The stock shows high profitability with a net margin of 33.42% and ROE of 35.74%, though valuation metrics like EV/EBITDA of 42.2 indicate premium pricing.
The outlook is positive with 70% analyst buy ratings and a $33 consensus target, but risks include reliance on key drugs and Phase 2 trial results for remlifanserin due by October 2026. Cash flow volatility from heavy investing outlays in 2025 warrants monitoring, but operational strength supports growth potential.
GRAB trades at $3.66, down 0.27% on the day, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $3.37B in 2025, with net income turning positive at $268M, reflecting improved profitability. The company raised its 2026 guidance, supported by growth in on-demand and financial services segments. Analyst sentiment is overwhelmingly positive, with 91.67% recommending Buy.
Outlook remains favorable due to sustained revenue growth and margin expansion, but risks include high valuation multiples and insider selling. The stock offers upside to the average price target of $5.86, though volatility from competitive pressures and macroeconomic headwinds warrants caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →
